TargetMol

AVE-9488

Product Code:
 
TAR-T30219
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30219-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30219-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30219-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AVE-9488 is a novel enhancer of endothelial NO synthase (eNOS).
CAS:
291756-32-6
Formula:
C17H13F2NO3
Molecular Weight:
317.29
Purity:
0.98
SMILES:
O=C(C1=CC=C(OC(F)(F)O2)C2=C1)NC3CC4=C(C=CC=C4)C3

References

1. Luna M, Karavitakis M. Treating portal hypertension in cirrhotic rats with AVE 9488. Liver Int. 2009 Oct;29(9):1448; author reply 1448-9. doi: 10.1111/j.1478-3231.2009.02093.x. Epub 2009 Jul 31. PubMed PMID: 19659506. 2. Frantz S, Adamek A, Fraccarollo D, Tillmanns J, Widder JD, Dienesch C, Sch?fer A, Podolskaya A, Held M, Ruetten H, Ertl G, Bauersachs J. The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol. 2009 Nov;104(6):773-9. doi: 10.1007/s00395-009-0041-3. Epub 2009 Jun 23. PubMed PMID: 19548059. 3. Sch?fer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G, Bauersachs J. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Eur J Heart Fail. 2009 Apr;11(4):336-41. doi: 10.1093/eurjhf/hfp005. Epub 2009 Feb 3. PubMed PMID: 19193626. 4. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation. 2008 Aug 19;118(8):818-27. doi: 10.1161/CIRCULATIONAHA.107.717702. Epub 2008 Aug 4. PubMed PMID: 18678774.